Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses

NCT04679909 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT04679909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04679909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses
Lead sponsor
Altimmune, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 25, 2021
Completion date
December 21, 2022
Enrollment
92 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers